https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-24 05:00:442020-08-18 13:49:45Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-16 11:08:172020-08-18 13:49:53Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-16 11:06:362020-06-08 10:49:55Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-09 05:00:122020-05-19 10:37:20FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00Lauren Fishhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgLauren Fish2019-04-12 05:48:132020-05-19 10:37:04Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-02-11 06:12:262020-05-19 10:36:43FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-01-31 15:12:552020-02-26 10:50:19Antimicrobials Working Group Announces Updates to Leadership Team
